弥漫大B细胞淋巴瘤患者病理组织中IQGAP2和CDC42表达及临床价值研究  

Study on the Expression and Clinical Value of IQGAP2 and CDC42 in Pathological Tissues of Patients with Diffuse Large B-cell Lymphoma

作　　者：陈铁桥 易小明 王云 王明明 张雨相[1] CHEN Tie-qiao;YI Xiao-ming;WANG Yun;WANG Ming-ming;ZHANG Yu-xiang(Department of Clinical Laboratory,the First Affiliated Hospital of Hunan College of Traditional Chinese Medicine/Hunan Provincial Hospital of Traditional Chinese Medicine,Hunan Zhuzhou 412000,China;Department of Clinical Laboratory,Yueyang Traditional Chinese Medicine Hospital,HunanYueyang 414021,China)

机构地区：[1]湖南中医药高等专科学校附属第一医院/湖南省直中医医院检验科,湖南株洲412000 [2]岳阳市中医医院检验科,湖南岳阳414021

出　　处：《现代检验医学杂志》2023年第3期72-78,共7页Journal of Modern Laboratory Medicine

基　　金：湖南省自然科学基金项目(编号:2019JJ80064):弥漫大B细胞淋巴瘤中含有IQ基序GTPase激活蛋白2,细胞分裂周期蛋白42的表达。

摘　　要：目的 研究弥漫大B细胞淋巴瘤(iffuse large B-cell lymphoma,DLBCL)患者病理组织中含有IQ基序GTPase激活蛋白2(IQ motif containing GTPase activating protein 2,IQGAP2)和细胞分裂周期蛋白42(cell division cycle 42,CDC42)的表达及临床意义。方法 选取2017年2月~2019年2月期间湖南省直中医医院诊治的83例初诊DLBCL患者为研究对象,以同期诊治的50例反应性淋巴结增生(reactive lymph node hyperplasia,RHL)患者为RLH组。应用免疫组织化学法及免疫印迹法检测组织中IQGAP2和CDC42的表达。比较不同临床病理特征患者DLBCL组织中IQGAP2和CDC42的表达差异。Kaplan-Meier生存分析IQGAP2和CDC42表达对DLBCL患者生存预后的影响。单因素和多因素COX回归分析影响DLBCL患者预后的因素。结果 DLBCL组中IQGAP2(83.13%),CDC42(85.54%)蛋白阳性率高于RLH组(8.00%,12.00%),差异均有统计学意义(χ^(2)=57.016,69.230,均P <0.05)。DLBCL组织中IQGAP2(1.21±0.23),CDC42(1.34±0.25)蛋白相对表达量高于RLH组织(0.61±0.18,0.75±0.21),差异具有统计学意义(t=15.759,14.377,均P<0.05)。Hans分型非GCB型,Ann Arbor临床分期Ⅲ~Ⅳ期组织中IQGAP2(90.00%vs 69.70%,91.67%vs 71.43%),CDC42(92.00%vs 75.76%,93.75%vs 74.29%)蛋白阳性率大于GCB型,Ⅰ~Ⅱ期,差异具有统计学意义(t=4.241~6.200,均P <0.05)。IQGAP2阳性组(50.72%vs 85.71%),CDC42阳性组(50.70%vs 91.67%)完全缓解率分别低于IQGAP2阴性组,CDC42阴性组,差异具有统计学意义(χ^(2)=5.801,7.013,均P<0.05)。IQGAP2阳性组(56.52%vs 85.71%),CDC42阳性组(56.34%vs 91.67%)三年总体生存率分别低于IQGAP2阴性组和CDC42阴性组患者,差异均有统计学意义(χ^(2)=4.318,4.963,均P<0.05)。Ann Arbor分期Ⅲ~Ⅳ期(OR=1.618,95%CI:1.019~2.569),IQGAP2阳性(OR=2.036,95%CI:1.174~3.532),CDC42阳性(OR=1.763,95%CI:1.114~2.789)是影响DLBCL患者生存预后的独立危险因素。结论 DLBCL组织中IQGAP2,CDC42表达升高,是影响DLBCL患者不良预后的独立因素,是新的DLBCL肿瘤标志物Objective To study the expression and clinical significance of GTPase-activating protein 2(IQGAP2)and mitotic cyclin 42(CDC42)in the pathological tissues of patients with diffuse large B-cell lymphoma(DLBCL).Methods A total of 83 newly diagnosed DLBCL patients diagnosed and treated in Hunan Provincial Directly Affiliated of Traditional Chinese Medicine Hospital from February 2017 to February 2019 were selected as the research objects,50 patients with reactive lymph node hyperplasia diagnosed and treated at the same time were taken as RLH group.The expressions of IQGAP2 and CDC42 in tissues were detected by immunohistochemistry and immunoblotting.The expression differences of IQGAP2 and CDC42 in DLBCL tissues of patients with different clinicopathological characteristics were compared.The effects of IQGAP2 and CDC42 expression on survival prognosis of DLBCL patients were analyzed by Kaplan-Meier survival analysis.Univariate and multivariate COX regression analysis were used to analyze factors affecting the prognosis of DLBCL patients.Results The positive rate of IQGAP2(83.13%)and CDC42(85.54%)protein in DLBCL group were higher than that in RLH group(8.00%,12.00%),the differences were statistically significant(χ^(2)=57.016,69.230,all P<0.05).The relative expression of IQGAP2(1.21±0.23)and CDC42(1.34±0.25)protein bands in DLBCL tissue was higher than that in RLH tissue(0.61±0.18,0.75±0.21),and the differences were statistically significant(t=15.759,14.377,all P<0.05).The positive rate of IQGAP2(90.00%vs 69.70%,91.67%vs 71.43%)and CDC42(92.00%vs 75.76%,93.75%vs 74.29%)in not GCB Hans type,Ann Arbor clinical stage III to IV were higher than that of GCB type,stage I to II,with statistically significant difference(t=4.241~6.200,all P<0.05).The complete remission rate of IQGAP2(50.72%vs 85.71%)and CDC42(50.70%vs 91.67%)positive group were significantly lower than that of IQGAP2 and CDC42 negative group,respectively(χ^(2)=5.801,7.013,all P<0.05).The 3-year overall survival rate of IQGAP2(56.52%vs 85.71%),CDC42(56.34

关 键 词：弥漫大B细胞淋巴瘤 含有IQ基序的GTPase激活蛋白2 细胞分裂周期蛋白42 

分 类 号：R733.4[医药卫生—肿瘤] R730.43[医药卫生—临床医学]